Platelet-Rich Plasma for the Treatment of Stress Urinary Incontinence-A Randomized Trial.
Journal
Urogynecology (Philadelphia, Pa.)
ISSN: 2771-1897
Titre abrégé: Urogynecology (Phila)
Pays: United States
ID NLM: 9918452588006676
Informations de publication
Date de publication:
01 Jun 2023
01 Jun 2023
Historique:
medline:
26
7
2023
pubmed:
26
7
2023
entrez:
26
7
2023
Statut:
aheadofprint
Résumé
Urinary incontinence affects millions of women worldwide. The aim of the current study was to evaluate the efficacy and safety of periurethral platelet-rich plasma (PRP) injections in women with stress urinary incontinence (SUI). This was a single-center, double-blind, randomized sham-controlled trial. Fifty participants with SUI and urodynamic stress incontinence were randomized in 2 equally sized groups. Women in the PRP group received 2 PRP injections at 3 levels of the urethra at 4- to 6-week intervals. Women in the sham group were injected with sodium chloride 0.9%. At baseline, participants underwent urodynamic studies and a 1-hour pad test and completed the International Consultation on Incontinence Questionnaire-Female Lower Urinary Tract Symptoms (ICIQ-FLUTS), the Patient Global Impression Scale of Improvement, and the King's Health Questionnaire. At follow-up visits (1, 3, and 6 months), women underwent the 1-hour pad test and completed the King's Health Questionnaire and the ICIQ-FLUTS. Primary outcome was the subjective evaluation as indicated by the response to question 11a of the ICIQ-FLUTS questionnaire. Secondary outcomes included scores of questionnaires and urine loss assessed on the 1-hour pad test. The level of discomfort during injections and any adverse events were also evaluated. During follow-up, the mean score of the 11a question decreased significantly in the PRP group compared with sham. Subjective cure was significantly higher in the PRP group (32% vs 4%, P < 0.001). A significant reduction of urine loss assessed on the 1-hour pad test was observed in the PRP group compared with the sham group at 6-month follow-up. No adverse events were observed. Periurethral PRP injections were superior to sham injections in improving SUI symptoms with an excellent safety profile.
Identifiants
pubmed: 37493287
doi: 10.1097/SPV.0000000000001378
pii: 02273501-990000000-00114
doi:
Banques de données
ClinicalTrials.gov
['NCT05112718']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2023 American Urogynecologic Society. All rights reserved.
Déclaration de conflit d'intérêts
The authors have declared they have no conflicts of interest.
Références
Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Neurourol Urodyn. 2010;29:4–20. doi:10.1002/nau.20798.
doi: 10.1002/nau.20798
Milsom I, Gyhagen M. The prevalence of urinary incontinence. Climacteric. 2019;22(3):217–222. doi:10.1080/13697137.2018.1543263.
doi: 10.1080/13697137.2018.1543263
Irwin DE, Milsom I, Kopp Z, et al. Impact of overactive bladder symptoms on employment, social interactions and emotional well-being in six European countries. BJU Int. 2006;97:96–100. doi:10.1111/j.1464-410X.2005.05889.x.
doi: 10.1111/j.1464-410X.2005.05889.x
Morrison A, Levy R. Fraction of nursing home admissions attributable to urinary incontinence. Value Health. 2006;9:272–274. doi:10.1111/j.1524-4733.2006.00109.x.
doi: 10.1111/j.1524-4733.2006.00109.x
Minassian VA, Drutz HP, Al-Badr A. Urinary incontinence as a worldwide problem. Int J Gynaecol Obstet. 2003;82(3):327–338. doi:10.1016/s0020-7292(03)00220-0.
doi: 10.1016/s0020-7292(03)00220-0
Evaluation of uncomplicated stress urinary incontinence in women before surgical treatment. Committee Opinion No. 603. American College of Obstetricians and Gynecologists. Obstet Gynecol. 2014;123:1403–1407. doi:10.1097/01.AOG.0000450759.34453.31.
doi: 10.1097/01.AOG.0000450759.34453.31
Capobianco G, Madonia M, Morelli S, et al. Management of female stress urinary incontinence: a care pathway and update. Maturitas. 2018;109:32–38. doi:10.1016/j.maturitas.2017.12.008.
doi: 10.1016/j.maturitas.2017.12.008
Kowalik CG, Dmochowski RR, De EJB. Surgery for female SUI: the ICI algorithm. Neurourol Urodyn. 2019;38(Suppl 4):S21–S27. doi:10.1002/nau.23879.
doi: 10.1002/nau.23879
Ostrzenski A. The new etiology and surgical therapy of stress urinary incontinence in women. Eur J Obstet Gynecol Reprod Biol. 2020;245:26–34. doi:10.1016/j.ejogrb.2019.11.023.
doi: 10.1016/j.ejogrb.2019.11.023
Ford AA, Rogerson L, Cody JD, et al. Mid-urethral sling operations for stress urinary incontinence in women. Cochrane Database Syst Rev. 2017, 7 Issue 7. Art. No.: CD006375. DOI: 10.1002/14651858.CD006375.pub4.
doi: 10.1002/14651858.CD006375.pub4
Karmakar D, Dwyer PL, Murray C, et al. Long-term effectiveness and safety of open Burch colposuspension vs retropubic midurethral sling for stress urinary incontinence—results from a large comparative study. Am J Obstet Gynecol. 2021;224(6):593.e1–593.e8. doi:10.1016/j.ajog.2020.11.043.
doi: 10.1016/j.ajog.2020.11.043
Daneshgari F, Kong W, Swartz M. Complications of mid urethral slings: important outcomes for future clinical trials. J Urol. 2008;180(5):1890–1897. doi:10.1016/j.juro.2008.07.029.
doi: 10.1016/j.juro.2008.07.029
Blaivas JG, Purohit RS, Benedon MS, et al. Safety considerations for synthetic sling surgery. Nat Rev Urol. 2015;12(9):481–509. doi:10.1038/nrurol.2015.183.
doi: 10.1038/nrurol.2015.183
Recommendations of the mesh pause clinical advisory group to medical directors and surgical teams. Published online from British Society of Urogynecology (BSUG). https://bsug.org.uk/budcms/includes/kcfinder/upload/files/info-leaflets/SUBMITTED-Mesh-Clinical-Advisory-Group---advice-FINAL-20thJulyPM.pdf. Accessed November 11, 2022.
Gupta S, Paliczak A, Delgado D. Evidence-based indications of platelet-rich plasma therapy. Expert Rev Hematol. 2021;14(1):97–108. doi:10.1080/17474086.2021.1860002. Epub 2020 Dec 17. PMID: 33275468.
doi: 10.1080/17474086.2021.1860002
Everts P, Onishi K, Jayaram P, et al. Platelet-rich plasma: new performance understandings and therapeutic considerations in 2020. Int J Mol Sci. 2020;21(20):7794. doi:10.3390/ijms21207794.
doi: 10.3390/ijms21207794
Alves R, Grimalt R. A review of platelet-rich plasma: history, biology, mechanism of action, and classification. Skin Appendage Disord. 2018;4(1):18–24. doi:10.1159/000477353.
doi: 10.1159/000477353
Stavros A, Themistoklis G, Niki K, et al. The validation of international consultation on incontinence questionnaires in the Greek language. Neurourol Urodyn. 2012;31:1141–1144. doi:10.1002/nau.22197.
doi: 10.1002/nau.22197
Krhut J, Zachoval R, Smith PP, et al. Pad weight testing in the evaluation of urinary incontinence. Neurourol Urodyn. 2014;33(5):507–510. doi:10.1002/nau.22436.
doi: 10.1002/nau.22436
Grigoriadis T, Giannoulis G, Zacharakis D, et al. The “1-3-5 cough test”: comparing the severity of urodynamic stress incontinence with severity measures of subjective perception of stress urinary incontinence. Int Urogynecol J. 2016;27(3):419–425. doi:10.1007/s00192-015-2808-4.
doi: 10.1007/s00192-015-2808-4
Jensen MP, Chen C, Brugger AM. Interpretation of visual analog scale ratings and change scores: a reanalysis of two clinical trials of postoperative pain. J Pain. 2003;4(7):407–414. doi:10.1016/S1526-5900(03)00716-8.
doi: 10.1016/S1526-5900(03)00716-8
Wein AJ. How much is enough and who says so? The case of the King's Health Questionnaire and overactive bladder. J Urol. 2005;173(3):908. doi:10.1097/01.ju.0000153536.91765.df.
doi: 10.1097/01.ju.0000153536.91765.df
Athanasiou S, Kalantzis C, Zacharakis D, et al. The use of platelet-rich plasma as a novel nonsurgical treatment of the female stress urinary incontinence: a prospective pilot study. Female Pelvic Med Reconstr Surg. 2021;27(11):e668–e672. doi:10.1097/SPV.0000000000001100.
doi: 10.1097/SPV.0000000000001100
Long CY, Lin KL, Shen CR, et al. A pilot study: effectiveness of local injection of autologous platelet-rich plasma in treating women with stress urinary incontinence. Sci Rep. 2021;11(1):1584. doi:10.1038/s41598-020-80598-2.
doi: 10.1038/s41598-020-80598-2
Behnia-Willison F, Nguyen TTT, Norbury AJ, et al. Promising impact of platelet rich plasma and carbon dioxide laser for stress urinary incontinence. Eur J Obstet Gynecol Reprod Biol X. 2020;5:100099. doi:10.1016/j.eurox.2019.100099.
doi: 10.1016/j.eurox.2019.100099
Li J, Ballim D, Rodriguez M, et al. The anti-proliferative function of the TGF-β1 signaling pathway involves the repression of the oncogenic TBX2 by its homologue TBX3. J Biol Chem. 2014;289(51):35633–35643. doi:10.1074/jbc.M114.596411.
doi: 10.1074/jbc.M114.596411
Ai G, Shao X, Meng M, et al. Epidermal growth factor promotes proliferation and maintains multipotency of continuous cultured adipose stem cells via activating STAT signal pathway in vitro. Medicine (Baltimore). 2017;96(30):e7607. doi:10.1097/MD.0000000000007607.
doi: 10.1097/MD.0000000000007607
Shibuya M. Vascular endothelial growth factor (VEGF) and its receptor (VEGFR) signaling in angiogenesis: a crucial target for anti- and pro-angiogenic therapies. Genes Cancer. 2011;2(12):1097–1105. doi:10.1177/1947601911423031.
doi: 10.1177/1947601911423031
Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev. 2008;22(10):1276–1312. doi:10.1101/gad.1653708.
doi: 10.1101/gad.1653708
Yun YR, Won JE, Jeon E, et al. Fibroblast growth factors: biology, function, and application for tissue regeneration. J Tissue Eng. 2010;2010:218142. doi:10.4061/2010/218142.
doi: 10.4061/2010/218142
Delancey JO. Why do women have stress urinary incontinence? Neurourol Urodyn. 2010;29(Suppl 1):S13–S17. doi:10.1002/nau.20888.
doi: 10.1002/nau.20888